Advertisement

Current Diabetes Reports

, Volume 2, Issue 3, pp 216–222 | Cite as

Skeletal muscle triglyceride: Marker or mediator of obesity-induced insulin resistance in type 2 diabetes mellitus?

  • Bret H. Goodpaster
  • David E. Kelley
Article

Abstract

The inability of insulin to stimulate glucose metabolism in skeletal muscle is a classic characteristic of type 2 diabetes, but this insulin resistance entails altered patterns of lipid metabolism as well. An association between intracellular triglyceride and insulin resistance has been well established in both human and animal studies of obesity-related insulin resistance and type 2 diabetes. Skeletal muscle’s ability to select substrate for fuel metabolism, a metabolic flexibility, is also lost in insulin resistance, and defects in fatty acid metabolism during fasting or postabsorptive conditions likely play an important role in lipid oversupply to insulinresistant muscle. These impairments appear to be at least indirectly centered on the ability of mitochondria to oxidize fatty acids, possibly through mediation of lipid metabolite levels such as ceramide or diacylglycerol, which are known to directly attenuate insulin signaling. Moreover, periodic use of muscle triglyceride by exercise may mediate the association between muscle triglyceride and insulin resistance. Thus, it appears that skeletal muscle triglyceride is perhaps a surrogate for other lipid species having a more direct effect on insulin action. Defining mechanisms by which dysregulation of fatty acid metabolism and persistent lipid oversupply alter insulin action may help to target more effective strategies to prevent or treat type 2 diabetes.

Keywords

Skeletal Muscle Insulin Resistance Fatty Acid Metabolism Skeletal Muscle Insulin Resistance Postabsorptive Condition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Carey DG, Jenkins AB, Campbell LV, et al.: Abdominal fat and insulin resistance in normal and overweight women. Diabetes 1996, 45:633–638.PubMedCrossRefGoogle Scholar
  2. 2.
    Goodpaster BH, Thaete FL, Kelley DE: Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 2000, 71:885–892.PubMedGoogle Scholar
  3. 3.
    Kelley DE, Slasky S, Janosky J: Skeletal muscle density: effects of obesity and type 2 diabetes mellitus. Am J Clin Nutr 1991, 54:509–515.PubMedGoogle Scholar
  4. 4.
    Goodpaster BH, Kelley DE, Wing RR, et al.: Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999, 48:839–847. Examines effects of diet-induced weight loss on skeletal muscle fat content and insulin resistance in obese subjects.PubMedCrossRefGoogle Scholar
  5. 5.
    Goodpaster BH, Kelley DE, Thaete FL, et al.: Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Phys 2000, 89:104–110.Google Scholar
  6. 6.
    Goodpaster BH, Thaete FL, Simoneau J-A, Kelley DE: Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997, 46:1579–1585.PubMedCrossRefGoogle Scholar
  7. 7.
    Simoneau J-A, Colberg SR, Thaete FL, Kelley DE: Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. FASEB J 1995, 9:273–278.PubMedGoogle Scholar
  8. 8.
    Boesch C, Slotboom J, Hoppeler H, Kreis R: In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn Reson Med 1997, 37:484–493.PubMedCrossRefGoogle Scholar
  9. 9.
    Szczepaniak LS, Babcock EE, Schick F, et al.: Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Phys 1999, 276:E977-E989.Google Scholar
  10. 10.
    Perseghin G, Scifo P, DeCobelli F, et al.: Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999, 48:1600–1606.PubMedCrossRefGoogle Scholar
  11. 11.
    Ross R, Goodpaster B, Kelley D, Boada F: Magnetic resonance imaging in human body composition research: from quantitative to qualitative tissue measurement. Ann N Y Acad Sci 2000, 904:12–17.PubMedCrossRefGoogle Scholar
  12. 12.
    Pan DA, Lillioja S, Kriketos AD, et al.: Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997, 46:983–988.PubMedCrossRefGoogle Scholar
  13. 13.
    Phillips DI, Caddy S, Ilic V, et al.: Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metab Clin Exp 1996, 45:947–950.PubMedGoogle Scholar
  14. 14.
    Goodpaster BH, Theriault R, Watkins SC, Kelley DE: Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism 2000, 49:467–472. Direct quantification of intracellular triglyceride performed in biopsy specimens of human subjects. Muscle triglycerides are decreased following diet-induced weight loss in obese patients with type 2 diabetes.PubMedCrossRefGoogle Scholar
  15. 15.
    Storlein L, Jenkins A, Chisholm D, et al.: Influence of dietary fat composition on development of insulin resistance in rats: relationship to muscle triglyceride and omega 3 fatty acids in muscle phospholipid. Diabetes 1991, 40:280–289.CrossRefGoogle Scholar
  16. 16.
    Shimabukuro M, Koyama K, Chen G, et al.: Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Nat Acad Sci U S A 1997, 94:4637–4641.CrossRefGoogle Scholar
  17. 17.
    Andres R, Cadar G, Zierler K: The quantitatively minor role of carbohydrate in oxidative metabolism by skeletal muscle in intact man in the basal state. J Clin Invest 1956, 35:671–682.PubMedGoogle Scholar
  18. 18.
    Colberg S, Simoneau J-A, Thaete FL, Kelley DE: Impaired FFA utilization by skeletal muscle in women with visceral obesity. J Clin Invest 1995, 95:1846–1853.PubMedGoogle Scholar
  19. 19.
    Kelley DE, Goodpaster BH, Wing RR, Simoneau J-A: Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity and weight loss. Am J Physiol 1999, 277:E1130-E1141. Reports impaired skeletal muscle fatty acid oxidation in obese subjects commensurate with insulin resistance and higher muscle lipid content. Effects of weight loss include improved insulin sensitivity and reduced fat storage within muscle, with little change in the ability of skeletal muscle to oxidize fatty acids.PubMedGoogle Scholar
  20. 20.
    Berk PD, Zhou S-L, Bradbury M, et al.: Characterization of membrane transport processes: lessons learned from the study of BSP, bilirubin, and fatty acid uptake. Semin Liver Dis 1996, 16:107–120.PubMedCrossRefGoogle Scholar
  21. 21.
    Sidossis LS, Stuart CA, Shulman GI, et al.: Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria. J Clin Invest 1996, 98:2244–2250.PubMedGoogle Scholar
  22. 22.
    Felber J-P, Ferrannini E, Golay A, et al.: Role of lipid oxidation in the pathogenesis of insulin resistance of obesity and type 2 diabetes. Diabetes 1987, 36:1341–1350.PubMedCrossRefGoogle Scholar
  23. 23.
    Groop LC, Saloranta C, Shank M, et al.: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1991, 72:96–107.PubMedCrossRefGoogle Scholar
  24. 24.
    Kelley DE, Mokan M, Simoneau J-A, Mandarino LJ: Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest 1993, 92:93–98.Google Scholar
  25. 25.
    Kelley DE, Simoneau J-A: Impaired FFA utilization by skeletal muscle in NIDDM. J Clin Invest 1994, 94:2349–2356.PubMedGoogle Scholar
  26. 26.
    Roden M, Price TB, Perseghin G, et al.: Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996, 97:2859–2865.PubMedGoogle Scholar
  27. 27.
    Boden G, Chen X, Ruiz J, et al.: Mechanisms of fatty acidinduced inhibition of glucose uptake. J Clin Invest 1994, 93:2438–2446.PubMedGoogle Scholar
  28. 28.
    Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785–789.PubMedCrossRefGoogle Scholar
  29. 29.
    Boden G, Chen X: Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995, 96:1261–1268.PubMedGoogle Scholar
  30. 30.
    Kelley DE, Mandarino LJ: Hyperglycemia normalizes insulinstimulated skeletal muscle glucose oxidation and storage in noninsulin-dependendent diabetes mellitus. J Clin Invest 1990, 86:1999–2007.PubMedGoogle Scholar
  31. 31.
    Thompson AL, Cooney GJ: Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes 2000, 49:1761–1765. Reports on the mechanism by which skeletal muscle lipid directly inhibits insulin stimulation of glucose metabolism.PubMedCrossRefGoogle Scholar
  32. 32.
    Itani SI, Zhou Q, Pories WJ, et al.: Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes 2000, 49:1353–1358.PubMedCrossRefGoogle Scholar
  33. 33.
    Laybutt DR, Schmitz-Peiffer S, Ruderman NB, et al.: Activation of protein kinase C epsilon may contribute to muscle insulin resistance induced by lipid accumulation during chronic glucose infusion in rats [abstract]. Diabetes 1997, 46:241A.Google Scholar
  34. 34.
    Dresner A, Laurent D, Marcucci M, et al.: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999, 103:253–259.PubMedCrossRefGoogle Scholar
  35. 35.
    Schmitz-Peiffer C: Signalling aspects of insulin resistance in skeletal muscle: mechanisms induced by lipid oversupply. Cell Signal 2000, 12:583–594. Excellent review of the mechanisms by which chronic lipid oversupply in muscle may cause insulin resistance.PubMedCrossRefGoogle Scholar
  36. 36.
    Sleeman MW, Donegan NP, Heller-Harrison R, et al.: Association of acyl CoA synthetase 1 with GLUT 4 containing vesicles. J Biol Chem 1998, 273:3122–3135.CrossRefGoogle Scholar
  37. 37.
    Turcotte LP: Fatty acid binding proteins and muscle lipid metabolism in skeletal muscle. In Biochemistry of Exercise. Edited by Hargreaves M. Champaign, IL: Human Kinetics; 1999:210–215.Google Scholar
  38. 38.
    Blaak EE, Wagenmakers AJM, Glatz JFC, et al.: Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. Am J Physiol 2000, 279:146–154.Google Scholar
  39. 39.
    Simoneau J-A, Veerkamp JH, Turcotte LP, Kelley DE: Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J 1999, 13:2051–2060.PubMedGoogle Scholar
  40. 40.
    McGarry JD, Brown NF: The mitochondrial carnitine palmitoyl transferase system: from concept to molecular analysis. Eur J Biochem 1997, 224:1–14.CrossRefGoogle Scholar
  41. 41.
    Saha AK, Vavvas T, Kurowski TG, et al.: Malonyl-CoA regulation in skeletal muscle: its link to cell citrate and the glucose-fatty acid cycle. Am J Physiol 1997, 272:E641-E648.PubMedGoogle Scholar
  42. 42.
    Ruderman NB, Saha AK, Vavvas D, et al.: Malonyl CoA as a metabolic switch and a regulator of insulin sensitivity. In Skeletal Muscle Metabolism in Exercise and Diabetes. Edited by Richter EA, Saltin B. New York: Plenum Press; 1998:263–270.Google Scholar
  43. 43.
    Kruszynska YE, Mulford MI, Baloga J, et al.: Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 1998, 47:1107–1113.PubMedCrossRefGoogle Scholar
  44. 44.
    Pendergrass M, Koval J, Vogt C, et al.: Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 1998, 47:387–394.PubMedCrossRefGoogle Scholar
  45. 45.
    Simoneau J-A, Kelley DE: Altered skeletal muscle glycolytic and oxidative capacities contribute to insulin resistance in NIDDM. J Appl Physiol 1997, 83:166–171.PubMedGoogle Scholar
  46. 46.
    Simoneau J-A, Kelley DE, Neverova M, Warden CH: Overexpression of muscle uncoupling protein-2 content in human obesity associates with reduced skeletal muscle lipid utilization. FASEB J 1998, 12:1739–1745.PubMedGoogle Scholar
  47. 47.
    Saltin B, Gollnick PD: Skeletal muscle adaptability: significance for metabolism and performance. In Handbook of Physiology. Section 10: Skeletal Muscle. Edited by Peachey LD et al. Baltimore, MD: Williams and Wilkins; 1983:555–631.Google Scholar
  48. 48.
    Kelley D, Reilly J, Veneman T, Mandarino LJ: Effect of insulin on skeletal muscle glucose storage, oxidation, and glycolysis in humans. Am J Physiol 1990, 258:E923-E929.PubMedGoogle Scholar
  49. 49.
    Henry RR, Wallace P, Olefsky JM: Effects of weight loss on mechanisms of hyperglycemia in obese non-insulindependent diabetes mellitus. Diabetes 1986, 35:990–998.PubMedCrossRefGoogle Scholar
  50. 50.
    Kelley DE, Wing R, Buonocore C, et al.: Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993, 77:1287–1293.PubMedCrossRefGoogle Scholar
  51. 51.
    Wing RR, Blair EH, Bononi P, et al.: Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994, 17:30–36.PubMedCrossRefGoogle Scholar
  52. 52.
    Wing RR, Blair E, Marcus M, et al.: Year-long weight loss treatment for obese patients with type 2 diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 1994, 97:354–362.PubMedCrossRefGoogle Scholar
  53. 53.
    Maggio CA, Pi-Sunyer FX: The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997, 20:1744–1766.PubMedGoogle Scholar
  54. 54.
    Wing RR, Koeske R, Epstein LH, et al.: Long-term effects of modest weight loss in type 2 diabetic patients. Arch Intern Med 1987, 147:1749–1753.PubMedCrossRefGoogle Scholar
  55. 55.
    Zurlo F, Lillioja S, Esposito-Del Puente A, et al.: Low ratio of fat to carbohydrate oxidation as a predictor of weight gain: a study of 24-h RQ. Am J Physiol 1990, 259(5 Pt 1):E650-E657.PubMedGoogle Scholar
  56. 56.
    Zurlo F, Nemeth PM, Choski RM, et al.: Whole body energy metabolism and skeletal muscle biochemical characteristics. Metabolism 1994, 43:481–486.PubMedCrossRefGoogle Scholar
  57. 57.
    Houmard JA, Shinebarger MH, Dolan PL, et al.: Exercise training increases GLUT-4 protein concentration in previously sedentary middle-aged men. Am J Physiol 1993, 264(6 Pt 1):E896-E901.PubMedGoogle Scholar
  58. 58.
    Koval JA, DeFronzo RA, O'Doherty RM, et al.: Regulation of hexokinase II activity and expression in human muscle by moderate exercise. Am J Physiol 1998, 274:E304-E308.PubMedGoogle Scholar
  59. 59.
    Bloch G, Chase JR, Meyer DB, et al.: In vivo regulation of rat muscle glycogen resynthesis after intense exercise. Am J Physiol 1994, 266(1 Pt 1):E85-E91.PubMedGoogle Scholar
  60. 60.
    Gollnick PD, Saltin B: Significance of skeletal muscle oxidative enzyme enhancement with endurance training. Clin Physiol 1982, 2:1–12.PubMedGoogle Scholar
  61. 61.
    Romijn JA, Coyle EF, Sidossis LS, et al.: Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. Am J Physiol 1993, 265:E380-E391.PubMedGoogle Scholar
  62. 62.
    Goodpaster BH, He J, Watkins S, Kelley DE: Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 2001, 86:5755–5761.PubMedCrossRefGoogle Scholar
  63. 63.
    Dyck DJ, Peters SJ, Glatz J, et al.: Functional differences in lipid metabolism in resting skeletal muscle of various fiber types. Am J Physiol 1997, 271:E340-E351.Google Scholar

Copyright information

© Current Science Inc. 2002

Authors and Affiliations

  • Bret H. Goodpaster
    • 1
  • David E. Kelley
  1. 1.Division of Endocrinology and MetabolismUniversity of PittsburghPittsburghUSA

Personalised recommendations